<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03822897</url>
  </required_header>
  <id_info>
    <org_study_id>HN10</org_study_id>
    <nct_id>NCT03822897</nct_id>
  </id_info>
  <brief_title>De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma</brief_title>
  <acronym>EVADER</acronym>
  <official_title>A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Canadian Cancer Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out whether radiotherapy to some of the lymph node areas&#xD;
      can be safely omitted to decrease side effects without increasing the risk of the tumour&#xD;
      coming back.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The standard or usual treatment for this disease includes radiotherapy or radiotherapy&#xD;
      combined with chemotherapy or antibody therapy.&#xD;
&#xD;
      These treatments are highly effective at curing most patients with HPV-related cancer of the&#xD;
      oropharynx, but short and long-term side effects from treatment can be significant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Time to first progress event or censoring in year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Time to death or censoring in year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local control</measure>
    <time_frame>5 years</time_frame>
    <description>Percentage of patients with local control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional Control</measure>
    <time_frame>5 years</time_frame>
    <description>Percentage of patients with regional control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional control</measure>
    <time_frame>5 years</time_frame>
    <description>Percentage of patients with local and regional control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant Metastasis-Free Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Time to distant metastasis or censoring in year</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Oropharyngeal Cancer</condition>
  <arm_group>
    <arm_group_label>Two Treatment Options</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Option #1 - Radiotherapy 35 fractions, 5/wk, 7 wks 70Gy/56Gy Cisplatin 100mg/m2 on day 1, 22 and 43 or 40mg mg/m2/wk for 7 wks&#xD;
Option #2 - Radiation only-35 fraction, 6/wk, 6wks 70Gy/56Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>35 fractions, 5/wk, 7 wks 70Gy/56Gy, or&#xD;
35 fractions, 6/wk, 6 wks, 70Gy/56Gy, or&#xD;
35 fractions, 5/wk, 7 wks OR 6/wk, 6 wks 70Gy/56Gy</description>
    <arm_group_label>Two Treatment Options</arm_group_label>
    <other_name>No available</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>100 mg/m2 on day 1, 22, and 43 or 40 mg/m2 /wk for 7 wks</description>
    <arm_group_label>Two Treatment Options</arm_group_label>
    <other_name>No available</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with pathologically proven diagnosis of HPV-related OPSCC&#xD;
&#xD;
          -  Clinical stage T1-3 N0-1 M0 (UICC/AJCC 8th Ed.)&#xD;
&#xD;
          -  Patients must be eligible for definitive RT or CRT&#xD;
&#xD;
          -  Must be â‰¥ 18 years of age&#xD;
&#xD;
          -  Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or&#xD;
             2&#xD;
&#xD;
          -  Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life&#xD;
             and health economics questionnaires in either English or French&#xD;
&#xD;
          -  Patient consent must be appropriately obtained in accordance with applicable local and&#xD;
             regulatory requirements. Each patient must sign a consent form prior to enrolment in&#xD;
             the trial to document their willingness to participate&#xD;
&#xD;
          -  Patients must be accessible for treatment and follow-up. Investigators must assure&#xD;
             themselves the patients enrolled on this trial will be available for complete&#xD;
             documentation of the treatment, adverse events, and follow-up.&#xD;
&#xD;
          -  In accordance with CCTG policy, protocol treatment is to begin within 3 weeks of&#xD;
             patient registration&#xD;
&#xD;
          -  Women/men of childbearing potential must have agreed to use a highly effective&#xD;
             contraceptive method&#xD;
&#xD;
          -  The following radiological investigations must be done within 8 weeks of&#xD;
             randomization: CT or MR of head and neck (MRI is recommended for base-of-tongue&#xD;
             primary tumors); PET-CT scan.&#xD;
&#xD;
          -  Patient must consent to provision of, and investigator(s) must confirm location and&#xD;
             commit to obtain a representation of formalin-fixed paraffin block of non-cytology&#xD;
             tumour tissue in order that the specific correlative marker assays described in&#xD;
             Section 12 (Correlative Studies) may be conducted. Please see the Correlative Manual&#xD;
             for details&#xD;
&#xD;
          -  Patient must consent to provision of samples of blood and plasma (for circulating cell&#xD;
             free DNA) in order that the specific correlative marker assays described may be&#xD;
             conducted.&#xD;
&#xD;
          -  Patients with prior or concurrent malignancy whose natural history or treatment does&#xD;
             not have the potential to interfere with the safety or efficacy assessment of the&#xD;
             investigational regimen are eligible for this trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous chemotherapy or radiotherapy treatment for head and neck cancer&#xD;
&#xD;
          -  Patients with an unknown primary.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Bratman</last_name>
    <role>Study Chair</role>
    <affiliation>Princess Margaret Cancer Centre, Toronto, ON</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wendy Parulekar</last_name>
    <phone>613-533-6430</phone>
    <email>wparulekar@ctg.queensu.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>BCCA - Centre for the North</name>
      <address>
        <city>Prince George</city>
        <state>British Columbia</state>
        <zip>V2M 7E9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Olson</last_name>
      <phone>250 645-7300</phone>
      <phone_ext>687489</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>BCCA - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Berthelet</last_name>
      <phone>604 877-6000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Dr. H. Bliss Murphy Cancer Centre</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Kingston Health Sciences Centre</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Odette Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>The Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>The Research Institute of the McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Hotel-Dieu de Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>CIUSSS de l'Estrie - Centre hospitalier</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle C. Gauthier</last_name>
      <phone>819 346-1110</phone>
      <phone_ext>14610</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 18, 2019</study_first_submitted>
  <study_first_submitted_qc>January 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2019</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

